STOCKHOLM, SE / ACCESS Newswire / March 28, 2025 /Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today ...
Received a "Study May Proceed” letter from the FDA to evaluate amezalpat in combination with atezolizumab (TECENTRIQ®) and ...
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant ...
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights ...
STOCKHOLM, SE / ACCESS Newswire / March 28, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today annou ...
Equillium's itolizumab showed improved longer-term outcomes in aGVHD despite missing primary endpoints. FDA feedback on ...
"With strongly anchored pipelines, key global partnerships and deliberate plans to navigate regulatory pathways, we believe ...
Per the study protocol, patients received itolizumab within 3-days of the first administration of high-dose corticosteroids with a treatment period from Days 1-99, and a follow-up period from Days 100 ...
Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Clinical Trials Arena on MSN21h
Epicrispr secures $68m for facioscapulohumeral muscular dystrophy therapy trialEpicrispr has raised $68m in the initial close of its Series B financing round to commence the clinical trial of EPI-321 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback